Reimagining Diabetes: From Molecular Mechanisms to Transformative Therapies

Jan 01–05, 2027 | Location to be Determined
Scientific Organizers: Anna Krook, Jennifer Green, and David Moller

  In Person
  On Demand
×

-

Jan 01–05, 2027 | Location to be Determined

Scientific Organizers: Anna Krook, Jennifer Green, and David Moller

Supported by the  Directors' Fund

***Meeting program subject to change.

Available Formats:   = In Person     = On Demand
Friday, January 1, 2027
Registration
4:00–8:00 PM
Welcome Mixer
6:00–8:00 PM
Saturday, January 2, 2027
Breakfast
7:00–8:00 AM
Welcome and Keynote Address
8:00–9:00 AM
Daniel J. Drucker †, Lunenfeld-Tanenbaum Research Institute
Novel Disease Spaces in Metabolic Disease, Breadth and Impact of GLP1 based Medicines (Including CV-Renal, Alzheimer’s and Neurodegenerative Disorders)
Fine Tuning our Understanding of Genetic Causes for Metabolic Disease
9:00–11:15 AM
Ruth J Loos †, University of Copenhagen
Identification of Genes and Genetic Loci Contributing to the Risk of Obesity and Related Traits
Melina Claussnitzer †, Broad Institute, Harvard Medical School and Massachusetts General Hospital
Moving from Variant to Function
Bart O. Roep †, Leiden University Medical Center
New Genetic Signal Modulating T1 Diabetes Risk
Short Talk(s) Chosen from Abstracts
Coffee Break
9:30–9:50 AM
Panel Discussion 1: Lessons from Diabetes-Obesity Clinical Trials
11:15–12:15 PM
Poster Setup
11:15–1:00 PM
On Own for Lunch
12:15–5:00 PM
Poster Viewing
1:00–10:00 PM
Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions
2:30–4:30 PM
Short Talks Chosen from Abstracts
Coffee Available
4:30–5:00 PM
New Mechanisms with Clinical Results
5:00–7:00 PM
David Moller, Third Rock Ventures
Overview of Emerging Clinical Trial Results - Impact and Implications
David Kendall †, Zealand Pharma
Amylin Biology-Rationale and Clinical Results
Scott Harris †, Altimmune Inc.
Harnessing Glucagon Agonism to Amplify Efficacy
Short Talk(s) Chosen from Abstracts
Social Hour with Dinner
7:00–8:00 PM
Posters
7:30–10:00 PM
Sunday, January 3, 2027
Breakfast
7:00–8:00 AM
Breakthrough Opportunities for Type 1 Diabetes and Preservation of Pancreatic B-Cell Mass-Function
8:00–11:00 AM
Matthias Hebrok †, University of California, San Francisco
Advances toward Realizing the Goal of Stem Cell-Derived Islet Replacement Therapies
Pedro Herrera †, University of Geneva
Regenerative Medicine, Islet Health, and Disease-Modifying Approaches
Kevan C. Herold †, Yale University
Clinical Trial Advances to Decode Beta Cell Resilience in Type 1 Diabetes: Cellular Pathways that Prevent Immune Destruction
Diane Mathis †, Harvard Medical School
Novel Therapies for Immunoprotection
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
Poster Setup
11:00–1:00 PM
On Own for Lunch
11:00–5:00 PM
Poster Viewing
1:00–10:00 PM
Career Roundtable
3:00–4:30 PM
Coffee Available
4:30–5:00 PM
Disease Biology and Novel Therapeutic Targets
5:00–7:00 PM
Anna Krook, Karolinska Institutet
Skeletal Muscle as a Player in Pathobiology and a Therapeutic Target Organ
Mitchell A. Lazar †, Perelman School of Medicine, University of Pennsylvania
Role of Adipose Tissue and Transcriptional Control of Metabolism
Alexander Pfeifer †, University of Bonn
Novel Therapeutic Approach to Augment Thermogenic Adipose Tissue
Short Talk(s) Chosen from Abstracts
Social Hour with Dinner
7:00–8:00 PM
Posters
7:30–10:00 PM
Monday, January 4, 2027
Breakfast
7:00–8:00 AM
Addressing Shortcomings and Expanding Use of Incretin-Based Therapies
8:00–11:00 AM
Philip Larsen †, Sixpeaks Bio AG
Residual Challenges: Weight Regain, Sarcopenia, Long-Term Weight Maintenance
Rotonya Carr †, University of Washington
Treating Metabolic Dysfunction-Associated Steatotic Liver Disease
Brian Finan †, Eli Lilly
Incretin based Tri Agonists
Lotte Bjerre Knudsen †, Novo Nordisk A/S
Incretin-based Therapeutics for the Treatment of Neurodegenerative Diseases
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
Poster Setup
11:00–1:00 PM
On Own for Lunch
11:00–5:00 PM
Poster Viewing
1:00–10:00 PM
Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions
2:30–4:30 PM
Short Talks Chosen from Abstracts
Coffee Available
4:30–5:00 PM
New Approaches Aimed at Modulating Energy Balance
5:00–7:00 PM
Randy J. Seeley †, University of Michigan
Neural Pathways Regulating Food Intake and Energy Balance
Katrin J. Svensson †, Stanford University
Novel Peptides (for Example: BRINP2-Related Peptide (BRP)) that Regulate Feeding and Obesity
Eleftheria Maratos-Flier †, Harvard Medical School and Alnylam
FGF21: What have we Learned from Mice and Human Trials?
Short Talk(s) Chosen from Abstracts
Social Hour with Dinner
7:00–8:00 PM
Posters
7:30–10:00 PM
Tuesday, January 5, 2027
Breakfast
7:00–8:00 AM
Clinical Technology Innovations & Devices
8:00–10:00 AM
Eric Topol †, The Scripps Research Institute
Approaches to Aging and Metabolic Disease Management
Emmanuel Opara †, Wake Forest Institute for Regenerative Medicine
The Bioartificial Pancreas
John Buse †, University of North Carolina School of Medicine
Glucose Sensing Insulin
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
Panel Discussion: What Does the Future Hold for Strategies to Predict, Prevent, and Treat Diabetes Mellitus
10:00–11:00 AM
* Jennifer Green, Duke University
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
11:00–11:15 AM
Wednesday, January 6, 2027
Departure
12:00–11:59 PM

Subscribe for Updates